{
    "clinical_study": {
        "@rank": "53712", 
        "arm_group": [
            {
                "arm_group_label": "IUI group", 
                "arm_group_type": "Active Comparator", 
                "description": "Group 1: Patients undergo a standard treatment with 3 consecutive gonadotrophin stimulated IUI cycles Intervention: treatment choice and drug:(Follitropine B\u00e8ta, Puregon, MSD).\nvs."
            }, 
            {
                "arm_group_label": "IVF/ICSI arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Group 2: 1 Patients start immediately with IVF/ICSI instead of IUI. A standard antagonist protocol with treatment with a recombinant FSH (Follitropine B\u00e8ta, Puregon, MSD) is used.\nIntervention: treatment choice and drug: recombinant FSH (Follitropine B\u00e8ta, Puregon,"
            }
        ], 
        "brief_summary": {
            "textblock": "Prospective randomised controlled trial: 3 IUI cycles versus 1 IVF/ICSI cycle in women aged\n      38-42 years."
        }, 
        "brief_title": "IUI vs. IVF/ICSI in Women Aged 38-42 Years: a Prospective Randomized Controlled Trial.", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "detailed_description": {
            "textblock": "Study design:\n\n      Prospective randomised controlled trial: 3 IUI cycles versus 1 IVF/ICSI cycle in women aged\n      38-42 years. .\n\n      Group 1: 3 consecutive gonadotrophin stimulated IUI cycles (Follitropine B\u00e8ta, Puregon,\n      MSD).\n\n      vs. Group 2: 1 IVF/ ICSI cycle - Recombinant FSH (Follitropine B\u00e8ta, Puregon, MSD) -\n      Antagonist protocol."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Women aged between 38 and 42 years. Sperm: use of donor sperm or husband sperm reaching\n        WHO criteria 2010.\n\n        Exclusion Criteria:\n\n          -  Tubal infertility (even one tube).\n\n          -  Major uterine or ovarian abnormalities\n\n          -  Metabolic abnormalities"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "42 Years", 
            "minimum_age": "38 Years"
        }, 
        "enrollment": {
            "#text": "138", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992731", 
            "org_study_id": "IUI versus IVF/ICSI"
        }, 
        "intervention": {
            "arm_group_label": [
                "IUI group", 
                "IVF/ICSI arm"
            ], 
            "intervention_name": "Drug: Follitropine B\u00e8ta", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Age (38-42 years)", 
            "pregnancy rates", 
            "3 IUI cycles", 
            "1 IVF/ICSI cycle"
        ], 
        "lastchanged_date": "November 19, 2013", 
        "location": {
            "contact": {
                "email": "mdebruck@vub.ac.be", 
                "phone": "024776699"
            }, 
            "facility": {
                "address": {
                    "city": "Jette", 
                    "country": "Belgium"
                }, 
                "name": "UniversitairZB"
            }, 
            "investigator": {
                "last_name": "Micha\u00ebl De Brucker, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "IUI vs. IVF/ICSI in Women Aged 38-42 Years: a Prospective Randomized Controlled Trial", 
        "overall_official": {
            "affiliation": "Universitair Ziekenhuis Brussel", 
            "last_name": "Michael De Brucker, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Belgium: FAGG", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Study design:\nProspective randomised controlled trial: 3 IUI cycles versus 1 IVF/ICSI cycle in women aged 38-42 years.\nGroup 1: 3 consecutive gonadotrophin stimulated IUI cycles (Follitropine B\u00e8ta, Puregon, MSD).\nvs. Group 2: 1 IVF/ ICSI cycle - Recombinant FSH (Follitropine B\u00e8ta, Puregon, MSD) - Antagonist protocol.\nPrimary endpoint:\nComparison of the cumulative ongoing pregnancy rates after 3 IUI cycles versus 1 IVF/ICSI cycle.", 
            "measure": "Ongoing pregnancy rate", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992731"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universitair Ziekenhuis Brussel", 
            "investigator_full_name": "Michael De Brucker", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Universitair Ziekenhuis Brussel", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitair Ziekenhuis Brussel", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}